These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26792124)

  • 21. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
    Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin.
    Yamamoto R; Nakae Y; Tanaka F; Johkura K
    J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1781-1785. PubMed ID: 27103270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
    Lu Y; Yang J; Zhang H; Yang J
    Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery.
    Abohelaika S; Wynne H; Avery P; Kamali F
    J Thromb Haemost; 2015 Aug; 13(8):1436-40. PubMed ID: 26010205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of an extended International Normalized Ratio follow-up interval on healthcare use among veteran patients on stable warfarin doses.
    Margolis AR; Porter AL; Staresinic CE; Ray CA
    Am J Health Syst Pharm; 2019 Oct; 76(22):1848-1852. PubMed ID: 31589272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
    Wallentin L; Yusuf S; Ezekowitz MD; Alings M; Flather M; Franzosi MG; Pais P; Dans A; Eikelboom J; Oldgren J; Pogue J; Reilly PA; Yang S; Connolly SJ;
    Lancet; 2010 Sep; 376(9745):975-83. PubMed ID: 20801496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation.
    Yaghi S; Liberman AL; Henninger N; Grory BM; Nouh A; Scher E; Giles J; Liu A; Nagy M; Kaushal A; Azher I; Fakhri H; Espaillat KB; Asad SD; Pasupuleti H; Martin H; Tan J; Veerasamy M; Esenwa C; Cheng N; Moncrieffe K; Moeini-Naghani I; Siddu M; Trivedi T; Ishida K; Frontera J; Lord A; Furie K; Keyrouz S; de Havenon A; Mistry E; Leon Guerrero CR; Khan M
    J Stroke Cerebrovasc Dis; 2020 Jul; 29(7):104888. PubMed ID: 32414583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new regimen for starting warfarin therapy in out-patients.
    Oates A; Jackson PR; Austin CA; Channer KS
    Br J Clin Pharmacol; 1998 Aug; 46(2):157-61. PubMed ID: 9723825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals.
    Anderson AM; Chane T; Patel M; Chen S; Xue W; Easley KA
    AIDS Patient Care STDS; 2012 Aug; 26(8):454-62. PubMed ID: 22742455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Search for predictors of nontherapeutic INR results with warfarin therapy.
    McGriff-Lee NJ; Csako G; Chen JT; Dang DK; Rosenfeld KG; Cannon RO; Macklin LR; Wesley RA;
    Ann Pharmacother; 2005 Dec; 39(12):1996-2002. PubMed ID: 16288081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized controlled trial of empiric warfarin dose reduction with the initiation of doxycycline therapy.
    Dowd MB; Kippes KA; Witt DM; Delate T; Martinez K
    Thromb Res; 2012 Aug; 130(2):152-6. PubMed ID: 22221937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation.
    Borgman MP; Pendleton RC; McMillin GA; Reynolds KK; Vazquez S; Freeman A; Wilson A; Valdes R; Linder MW
    Thromb Haemost; 2012 Sep; 108(3):561-9. PubMed ID: 22836303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
    JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between the Prothrombin Time-International Normalized Ratio and Concomitant Use of Antibiotics in Warfarin Users: Focus on Type of Antibiotic and Susceptibility of
    Yagi T; Naito T; Kato A; Hirao K; Kawakami J
    Ann Pharmacother; 2021 Feb; 55(2):157-164. PubMed ID: 32633584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of prophylactic oseltamivir on INR in patients on stable warfarin therapy.
    Smith KR; Bryan WE; Townsend ML; Randolph AE; Vanderman AJ; Woodard CL; Brown JN
    J Thromb Thrombolysis; 2020 Aug; 50(2):452-456. PubMed ID: 31898274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.
    Nakamura A; Kuroda J; Ago T; Hata J; Matsuo R; Arakawa S; Kuwashiro T; Yasaka M; Okada Y; Kitazono T; Kamouchi M;
    Cerebrovasc Dis; 2016; 42(3-4):196-204. PubMed ID: 27111222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Taking Warfarin with Subtherapeutic INR.
    Mowla A; Memon A; Razavi SM; Lail NS; Vaughn CB; Mohammadi P; Sawyer RN; Shirani P
    J Stroke Cerebrovasc Dis; 2021 May; 30(5):105678. PubMed ID: 33640783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
    Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
    Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.